Inhibition of colony-stimulating-factor-1 signalingin vivowith the orally bioavailable cFMS kinase inhibitor GW2580
Open Access
- 25 October 2005
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 102 (44), 16078-16083
- https://doi.org/10.1073/pnas.0502000102
Abstract
Colony-stimulating-factor-1 (CSF-1) signaling through cFMS receptor kinase is increased in several diseases. To help investigate the role of cFMS kinase in disease, we identified GW2580, an orally bioavailable inhibitor of cFMS kinase. GW2580 completely inhibited human cFMS kinase in vitro at 0.06 μM and was inactive against 26 other kinases. GW2580 at 1 μM completely inhibited CSF-1-induced growth of mouse M-NFS-60 myeloid cells and human monocytes and completely inhibited bone degradation in cultures of human osteoclasts, rat calvaria, and rat fetal long bone. In contrast, GW2580 did not affect the growth of mouse NS0 lymphoblastoid cells, human endothelial cells, human fibroblasts, or five human tumor cell lines. GW2580 also did not affect lipopolysaccharide (LPS)-induced TNF, IL-6, and prostaglandin E2 production in freshly isolated human monocytes and mouse macrophages. After oral administration, GW2580 blocked the ability of exogenous CSF-1 to increase LPS-induced IL-6 production in mice, inhibited the growth of CSF-1-dependent M-NFS-60 tumor cells in the peritoneal cavity, and diminished the accumulation of macrophages in the peritoneal cavity after thioglycolate injection. Unexpectedly, GW2580 inhibited LPS-induced TNF production in mice, in contrast to effects on monocytes and macrophages in vitro. In conclusion, GW2580's selective inhibition of monocyte growth and bone degradation is consistent with cFMS kinase inhibition. The ability of GW2580 to chronically inhibit CSF-1 signaling through cFMS kinase in normal and tumor cells in vivo makes GW2580 a useful tool in assessing the role of cFMS kinase in normal and disease processes.Keywords
This publication has 47 references indexed in Scilit:
- Regulation of receptor activator of nuclear factor-κB ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow culturesBone, 2002
- TNF Potently Activates Osteoclasts, through a Direct Action Independent of and Strongly Synergistic with RANKLEndocrinology, 2002
- Expression of macrophage‐colony stimulating factor in normal and inflammatory bowel disease intestineThe Journal of Pathology, 2001
- The Activated Macrophage Colony-Stimulating Factor (CSF-1) Receptor as a Predictor of Poor Outcome in Advanced Epithelial Ovarian CarcinomaGynecologic Oncology, 2001
- Differential expression of transforming growth factor‐α and macrophage colony‐stimulating factor/colony‐stimulating factor‐1R (c‐fms) by multinucleated giant cells involved in pathological bone resorption at the site of orthopaedic implantsJournal of Orthopaedic Research, 2000
- M-CSF neutralization and Egr-1 deficiency prevent ovariectomy-induced bone lossJCI Insight, 2000
- Direct Comparison of the Effects of CSF-1 (M-CSF) and GM-CSF on Human Monocyte DNA Synthesis and CSF Receptor ExpressionJournal of Interferon & Cytokine Research, 1999
- Colony stimulating factor-1 plays a role in osteoclast formation and function in bone resorption induced by parathyroid hormone and parathyroid hormone-related proteinJournal of Bone and Mineral Research, 1996
- CONSTITUTIVE mRNA AND PROTEIN PRODUCTION OF MACROPHAGE COLONY-STIMULATING FACTOR BUT NOT OF OTHER CYTOKINES BY SYNOVIAL FIBROBLASTS FROM RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS PATIENTSRheumatology, 1994
- Examination of survival, proliferation and cell surface antigen expression of human monocytes exposed to macrophage colony‐stimulating factor (M‐CSF)The International Journal of Cell Cloning, 1990